Literature DB >> 17004033

Prevention of membrane damage in patient on peritoneal dialysis with new peritoneal dialysis solutions.

Mufazzal Ahmad1, Hemal Shah, Theodori Pliakogiannis, Dimitrios G Oreopoulos.   

Abstract

Peritoneal dialysis (PD) is now an established and successful alternative to hemodialysis. Multiple studies have confirmed its equivalent dialysis adequacy, mortality and fluid balance status, at least for the first 4-5 years. Peritoneal membrane failure is now one of the leading cause of technique failure. This review describes the role of glucose, glucose degradation product, pH, lactate, advanced glycosylation end product (AGE) in causing this membrane damage, and gives insight how the use of newer peritoneal dialysis fluids (PDFs) containing icodextrin, amino acids and bicarbonate buffer can prevent peritoneal membrane damage.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17004033     DOI: 10.1007/s11255-006-9064-y

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.266


  85 in total

1.  European best practice guidelines for peritoneal dialysis. 5 Peritoneal dialysis solutions.

Authors:  Nicholas Dombros; Max Dratwa; Mariano Feriani; Ram Gokal; Olof Heimbürger; Raymond Krediet; Jörg Plum; Anabela Rodrigues; Rafael Selgas; Dirk Struijk; Christian Verger
Journal:  Nephrol Dial Transplant       Date:  2005-12       Impact factor: 5.992

2.  Clinical evaluation of a peritoneal dialysis solution with 33 mmol/L bicarbonate.

Authors:  G C Cancarini; D Faict; C De Vos; R Guiberteau; A Tranaeus; L Minetti; R Maiorca
Journal:  Perit Dial Int       Date:  1998 Nov-Dec       Impact factor: 1.756

3.  A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis.

Authors:  Marsha Wolfson; Beth Piraino; Richard J Hamburger; A Ross Morton
Journal:  Am J Kidney Dis       Date:  2002-11       Impact factor: 8.860

4.  Toxicity of osmotic solutes on human mesothelial cells in vitro.

Authors:  A Breborowicz; H Rodela; D G Oreopoulos
Journal:  Kidney Int       Date:  1992-05       Impact factor: 10.612

5.  Improved biocompatibility of bicarbonate/lactate-buffered PDF is not related to pH.

Authors:  Mohammad Zareie; Eelco D Keuning; Piet M ter Wee; Casper G Schalkwijk; Robert H J Beelen; Jacob van den Born
Journal:  Nephrol Dial Transplant       Date:  2005-11-01       Impact factor: 5.992

6.  Aseptic peritonitis due to peptidoglycan contamination of pharmacopoeia standard dialysis solution.

Authors:  Leo Martis; Mehul Patel; Joe Giertych; Jim Mongoven; Michel Taminne; Michele A Perrier; Omar Mendoza; Niranjan Goud; Aidan Costigan; Nicole Denjoy; Christian Verger; William F Owen
Journal:  Lancet       Date:  2005 Feb 12-18       Impact factor: 79.321

7.  Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance).

Authors:  Ho Yung Lee; Hyeong Cheon Park; Bo Jeung Seo; Jun Young Do; Sung Ro Yun; Hyun Yong Song; Yeong Hoon Kim; Yong Lim Kim; Dae Joong Kim; Yong Soo Kim; Curie Ahn; Moon Jae Kim; Sug Kyun Shin
Journal:  Perit Dial Int       Date:  2005 May-Jun       Impact factor: 1.756

8.  Biocompatibility of a glucose-polymer-containing peritoneal dialysis fluid.

Authors:  C W de Fijter; H A Verbrugh; L P Oe; E Heezius; A J Donker; J Verhoef; R Gokal
Journal:  Am J Kidney Dis       Date:  1993-04       Impact factor: 8.860

9.  Glucose degradation products (GDP) retard remesothelialization independently of D-glucose concentration.

Authors:  Llinos W Morgan; Anders Wieslander; Malcolm Davies; Takashi Horiuchi; Yuji Ohta; M Janine Beavis; Kathryn J Craig; John D Williams; Nicholas Topley
Journal:  Kidney Int       Date:  2003-11       Impact factor: 10.612

10.  Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study.

Authors:  Andreas Fusshoeller; Marcus Plail; Bernd Grabensee; Joerg Plum
Journal:  Nephrol Dial Transplant       Date:  2004-06-22       Impact factor: 5.992

View more
  6 in total

Review 1.  Statin therapy in peritoneal dialysis patients: effects beyond lipid lowering.

Authors:  Kosmas I Paraskevas
Journal:  Int Urol Nephrol       Date:  2007-12-08       Impact factor: 2.370

2.  The promising future of long-term peritoneal dialysis.

Authors:  Dimitrios Oreopoulos; Elias Thodis; Kosmas I Paraskevas
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

3.  No need for an "expiry date" in chronic peritoneal dialysis to prevent encapsulating peritoneal sclerosis.

Authors:  Guido Garosi; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2009-12       Impact factor: 2.370

4.  Role of miRNA-21/PTEN on the high glucose-induced EMT in human mesothelial peritoneal cells.

Authors:  Lina Yang; Yi Fan; Xiuli Zhang; Lili Gao; Jianfei Ma
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

5.  Two icodextrin exchanges per day in peritoneal dialysis patients with ultrafiltration failure: one center's experience and review of the literature.

Authors:  Periklis Dousdampanis; Konstantza Trigka; Maggie Chu; Saimah Khan; Daniele Venturoli; Dimitrios G Oreopoulos; Joanne M Bargman
Journal:  Int Urol Nephrol       Date:  2010-02-21       Impact factor: 2.370

6.  Prolonged use of the tyrosine kinase inhibitor in a peritoneal dialysis patient with metastatic renal cell carcinoma: possible beneficial effects on peritoneal membrane and peritonitis rates.

Authors:  Shruti N Tapiawala; Joanne M Bargman; Dimitrios G Oreopoulos; Martin Simons
Journal:  Int Urol Nephrol       Date:  2009-03-03       Impact factor: 2.370

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.